98%
921
2 minutes
20
The primary objective of this study was to investigate the effects of prolonged heroin exposure on adult male rats. Our findings demonstrate that this intervention induces deficits in memory, synaptic plasticity, emotional regulation, and motor function. These impairments appear to be associated with reduced levels of BDNF, increased expression of REST/NRSF, and elevated astrocyte activity within the hippocampus. We employed a multimodal approach to assess the impact of heroin in 24 adult male rats following 2 weeks of daily injections. Behavioral assessments were conducted to evaluate memory and anxiety-like and depression-like behaviors, followed by tests of neuromuscular and locomotor function. Molecular and histological analyses were subsequently performed to characterize heroin-induced alterations in the brain. Heroin-treated rats showed impaired performance in cognitive tasks, evidenced by reduced scores in the Y-maze and shuttle box tests. Furthermore, heroin exposure negatively affected behavioral scores in the open field test, tail suspension test, and elevated plus maze. Electromyography (EMG) revealed increased latency, indicating disruptions in neuromuscular activity. Indicators of long-term potentiation (LTP), including population spike amplitude, and field EPSP slope, were significantly reduced following heroin administration. Immunohistochemical analysis revealed marked astrogliosis and alterations in BDNF and REST expression in the CA1 region of the hippocampus. Additionally, heroin disrupted the spatial organization of neurons. In conclusion, these results suggest that heroin exposure induces structural and functional neuronal changes, likely mediated by neuroinflammation and dysregulated neurotrophic signaling, which may underlie the observed cognitive impairments.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12183149 | PMC |
http://dx.doi.org/10.1007/s13205-025-04387-2 | DOI Listing |
Front Pediatr
August 2025
Tufts Clinical and Translational Science Institute, Boston, MA, United States.
Objective: Development and validation of a clinical prediction model for receipt of pharmacotherapy for Neonatal Abstinence Syndrome (NAS).
Study Design: Data from three cohorts included opioid exposed neonates ≥37 weeks gestation. Primary outcome was the receipt of pharmacotherapy utilizing a modified Finnegan Neonatal Abstinence Scoring System (FNASS).
JAMA Netw Open
August 2025
Division of Alcohol, Drugs and Addiction, McLean Hospital, Belmont, Massachusetts.
Importance: Several large, randomized clinical trials have tested the efficacy of adding behavioral therapy to medical management (high-quality, low-intensity medical counseling) and buprenorphine treatment of opioid use disorder. These studies have consistently reported strong rates of treatment response overall, without a significant additive benefit of additional behavioral therapy.
Objective: To address gaps in knowledge about additional behavioral therapy for patients receiving buprenorphine, including the association of additional behavioral therapy with retention and functional outcomes, and whether certain subgroups respond better to additional behavioral therapy.
Eur J Prev Cardiol
August 2025
School of Medicine, University of St Andrews, North Haugh, St Andrews, Scotland, KY16 9TF.
Aim: Chronic opioid exposure (COE) is linked to adverse health outcomes, but its relationship with cardiovascular disease (CVD) remains unclear. This systematic review and meta-analysis aimed to summarise published evidence on CVD risk associated with COE, including prescription opioids, opium use, and opioid use disorder (OUD).
Methods: Following PRISMA guidelines and PROSPERO registration (CRD42024573206), we searched multiple databases for relevant human studies reporting associations between COE and CVD.
Objectives: This study explored the correlations between childhood trauma, chronic pain, and substance use among individuals receiving methadone for opioid use disorder (OUD). We hypothesized that, among individuals with OUD, a history of childhood trauma would correlate with more severe pain and substance use compared with those without such history.
Methods: We conducted a cross-sectional study of 82 individuals receiving methadone for OUD.
Drug Alcohol Depend
September 2025
American College of Medical Toxicology, Phoenix, AZ, United States.
Background: Bromazolam, an illegal benzodiazepine, has recently increased in toxicological samples in the United States. Little is known about other substances detected with bromazolam and use intentions. This study investigated bromazolam's prevalence, co-occurring substances, and self-reported substance use among patients with bromazolam exposure presenting to emergency departments (ED) for opioid/stimulant-related non-fatal overdose.
View Article and Find Full Text PDF